Abstract
Drug repurposing has become one of the most widely used methods that can make drug discovery more efficient and less expensive. Additionally, computational methods such as structure-based drug designing can be utilized to make drug discovery more efficient and more accurate. Now imagine what can be achieved by combining drug repurposing and computational methods together in drug discovery, “in silico repurposing.” In this chapter, we tried to describe a method that combines structure-based virtual screening and molecular dynamics simulation which can find effective compounds among existing drugs that may affect on a specific molecular target. By using molecular docking as a tool for the screening process and then by calculating ligand binding in an active receptor site using scoring functions and inspecting the proper orientation of pharmacophores in the binding site, the potential compounds will be chosen. After that, in order to test the potential compounds in a realistic environment, molecular dynamics simulation and related analysis have to be carried out for separating the false positives and the true positives from each other and finally identifying true “Hit” compounds. It’s good to emphasize that if any of these identified potential compounds turn out to have the efficacy to affect that specific molecular target, it can be taken to the phase 2 clinical trials straightaway.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Chong CR, Sullivan DJ Jr (2007) New uses for old drugs. Nature 448(7154):645–646. https://doi.org/10.1038/448645a
Ciociola AA, Cohen LB, Kulkarni P, Gastroenterology FD-RMCotACo (2014) How drugs are developed and approved by the FDA: current process and future directions. Am J Gastroenterol 109(5):620–623. https://doi.org/10.1038/ajg.2013.407
Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3(5):417–429. https://doi.org/10.1038/nrd1382
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151–185. https://doi.org/10.1016/S0167-6296(02)00126-1
Ekins S, Williams AJ, Krasowski MD, Freundlich JS (2011) In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today 16(7-8):298–310. https://doi.org/10.1016/j.drudis.2011.02.016
Cavalla D (2013) Predictive methods in drug repurposing: gold mine or just a bigger haystack? Drug Discov Today 18(11-12):523–532. https://doi.org/10.1016/j.drudis.2012.12.009
Gupta SC, Sung B, Prasad S, Webb LJ, Aggarwal BB (2013) Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34(9):508–517. https://doi.org/10.1016/j.tips.2013.06.005
Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT (2016) In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 8(3):186–210. https://doi.org/10.1002/wsbm.1337
Liu Z, Fang H, Reagan K, Xu X, Mendrick DL, Slikker W Jr, Tong W (2013) In silico drug repositioning: what we need to know. Drug Discov Today 18(3-4):110–115. https://doi.org/10.1016/j.drudis.2012.08.005
Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3(11):935–949. https://doi.org/10.1038/nrd1549
Leelananda SP, Lindert S (2016) Computational methods in drug discovery. Beilstein J Organ Chem 12:2694–2718. https://doi.org/10.3762/bjoc.12.267
Anderson AC (2003) The process of structure-based drug design. Chem Biol 10(9):787–797
Lounnas V, Ritschel T, Kelder J, McGuire R, Bywater RP, Foloppe N (2013) Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery. Comput Struct Biotechnol J 5:e201302011. https://doi.org/10.5936/csbj.201302011
Kaul PN (1998) Drug discovery: past, present and future. Prog Drug Res 50:9–105
Mandal S, Moudgil M, Mandal SK (2009) Rational drug design. Eur J Pharmacol 625(1-3):90–100. https://doi.org/10.1016/j.ejphar.2009.06.065
Mavromoustakos T, Durdagi S, Koukoulitsa C, Simcic M, Papadopoulos MG, Hodoscek M, Grdadolnik SG (2011) Strategies in the rational drug design. Curr Med Chem 18(17):2517–2530
Wang T, Wu MB, Zhang RH, Chen ZJ, Hua C, Lin JP, Yang LR (2016) Advances in computational structure-based drug design and application in drug discovery. Curr Top Med Chem 16(9):901–916
Marrone TJ, Briggs JM, McCammon JA (1997) Structure-based drug design: computational advances. Annu Rev Pharmacol Toxicol 37:71–90. https://doi.org/10.1146/annurev.pharmtox.37.1.71
Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quintas-Cardama A (2014) Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A 111(9):3550–3555. https://doi.org/10.1073/pnas.1321173111
Rester U (2008) From virtuality to reality - virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective. Curr Opin Drug Discov Devel 11(4):559–568
Persidis A (1998) High-throughput screening. Advances in robotics and miniturization continue to accelerate drug lead identification. Nat Biotechnol 16(5):488–489. https://doi.org/10.1038/nbt0598-488
Wilkinson GF, Pritchard K (2015) In vitro screening for drug repositioning. J Biomol Screen 20(2):167–179. https://doi.org/10.1177/1087057114563024
Rollinger JM, Stuppner H, Langer T (2008) Virtual screening for the discovery of bioactive natural products. Prog Drug Res 65(211):213–249
Shoichet BK (2004) Virtual screening of chemical libraries. Nature 432(7019):862–865. https://doi.org/10.1038/nature03197
Lionta E, Spyrou G, Vassilatis DK, Cournia Z (2014) Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem 14(16):1923–1938
Meng XY, Zhang HX, Mezei M, Cui M (2011) Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 7(2):146–157
Jones G, Willett P, Glen RC, Leach AR, Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267(3):727–748. https://doi.org/10.1006/jmbi.1996.0897
Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein–ligand docking using GOLD. Proteins 52(4):609–623. https://doi.org/10.1002/prot.10465
Allen WJ, Balius TE, Mukherjee S, Brozell SR, Moustakas DT, Lang PT, Case DA, Kuntz ID, Rizzo RC (2015) DOCK 6: impact of new features and current docking performance. J Comput Chem 36(15):1132–1156. https://doi.org/10.1002/jcc.23905
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455–461. https://doi.org/10.1002/jcc.21334
Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47(7):1750–1759. https://doi.org/10.1021/jm030644s
Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49(21):6177–6196. https://doi.org/10.1021/jm051256o
Ledock. Ledock www.lephar.com
Chang DT, Oyang YJ, Lin JH (2005) MEDock: a web server for efficient prediction of ligand binding sites based on a novel optimization algorithm. Nucleic Acids Res 33(Web Server Issue):W233–W238
Grosdidier A, Zoete V, Michielin O (2011) SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 39(Web Server Issue):W270–W277. https://doi.org/10.1093/nar/gkr366
Wu P, Nielsen TE, Clausen MH (2015) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36(7):422–439. https://doi.org/10.1016/j.tips.2015.04.005
Liu J, Wang R (2015) Classification of current scoring functions. J Chem Inf Model 55(3):475–482. https://doi.org/10.1021/ci500731a
Huang S-Y, Grinter SZ, Zou X (2010) Scoring functions and their evaluation methods for protein-ligand docking: recent advances and future directions. Phys Chem Chem Phys 12(40):12899–12908. https://doi.org/10.1039/C0CP00151A
Jain AN (2006) Scoring functions for protein-ligand docking. Curr Protein Pept Sci 7(5):407–420
Perola E, Walters WP, Charifson PS (2004) A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance. Proteins 56(2):235–249. https://doi.org/10.1002/prot.20088
Wang JC, Lin JH (2013) Scoring functions for prediction of protein-ligand interactions. Curr Pharm Des 19(12):2174–2182
Neudert G, Klebe G (2011) DSX: a knowledge-based scoring function for the assessment of protein-ligand complexes. J Chem Inf Model 51(10):2731–2745. https://doi.org/10.1021/ci200274q
Krammer A, Kirchhoff PD, Jiang X, Venkatachalam CM, Waldman M (2005) LigScore: a novel scoring function for predicting binding affinities. J Mol Graph Model 23(5):395–407. https://doi.org/10.1016/j.jmgm.2004.11.007
Wang R, Lu Y, Wang S (2003) Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem 46(12):2287–2303. https://doi.org/10.1021/jm0203783
Kalyaanamoorthy S, Chen Y-PP (2011) Structure-based drug design to augment hit discovery. Drug Discov Today 16(17):831–839. https://doi.org/10.1016/j.drudis.2011.07.006
McCammon JA, Gelin BR, Karplus M (1977) Dynamics of folded proteins. Nature 267:585. https://doi.org/10.1038/267585a0
Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham TE (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33(12):889–897. https://doi.org/10.1021/ar000033j
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28(1):235–242
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605–1612. https://doi.org/10.1002/jcc.20084
Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen M-y, Pieper U, Sali A (2006) Comparative protein structure modeling using modeller. Curr Protoc Bioinformatics 5:Unit-5.6. https://doi.org/10.1002/0471250953.bi0506s15
Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34(Database issue):D668–D672. https://doi.org/10.1093/nar/gkj067
O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open babel: an open chemical toolbox. J Chem 3:33. https://doi.org/10.1186/1758-2946-3-33
Xu W, Lim J, Goh C-Y, Suen JY, Jiang Y, Yau M-K, Wu K-C, Liu L, Fairlie DP (2015) Repurposing registered drugs as antagonists for protease-activated receptor 2. J Chem Inf Model 55(10):2079–2084. https://doi.org/10.1021/acs.jcim.5b00500
Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der Spoel D, Hess B, Lindahl E (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29(7):845–854. https://doi.org/10.1093/bioinformatics/btt055
Sousa da Silva AW, Vranken WF (2012) ACPYPE - AnteChamber PYthon Parser interfacE. BMC Res Notes 5:367. https://doi.org/10.1186/1756-0500-5-367
Kumari R, Kumar R, Open Source Drug Discovery C, Lynn A (2014) g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations. J Chem Inf Model 54(7):1951–1962. https://doi.org/10.1021/ci500020m
Sohraby F, Bagheri M, Aliyar M, Aryapour H (2017) In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: a virtual screening and molecular dynamics study. J Mol Graph Model 74:234–240. https://doi.org/10.1016/j.jmgm.2017.04.005
Sohraby F, Bagheri M, Javaheri Moghadam M, Aryapour H (2017) In silico prediction of new inhibitors for the nucleotide pool sanitizing enzyme, MTH1, using drug repurposing. J Biomol Struct Dyn:1–9. https://doi.org/10.1080/07391102.2017.1365013
Aryapour H, Dehdab M, Sohraby F, Bargahi A (2017) Prediction of new chromene-based inhibitors of tubulin using structure-based virtual screening and molecular dynamics simulation methods. Comput Biol Chem 71(Suppl C):89–97. https://doi.org/10.1016/j.compbiolchem.2017.09.007
Mofidifar S, Sohraby F, Bagheri M, Aryapour H (2018) Repurposing existing drugs for new AMPK activators as a strategy to extend lifespan: a computer-aided drug discovery study. Biogerontology 19:133. https://doi.org/10.1007/s10522-018-9744-x
Stierand K, Rarey M (2010) PoseView -- molecular interaction patterns at a glance. J Chem 2(1):P50. https://doi.org/10.1186/1758-2946-2-s1-p50
Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8(2):127–134. https://doi.org/10.1093/protein/8.2.127
Wang Z, Sun H, Yao X, Li D, Xu L, Li Y, Tian S, Hou T (2016) Comprehensive evaluation of ten docking programs on a diverse set of protein-ligand complexes: the prediction accuracy of sampling power and scoring power. Phys Chem Chem Phys 18(18):12964–12975. https://doi.org/10.1039/c6cp01555g
He Z, Zhang J, Shi XH, Hu LL, Kong X, Cai YD, Chou KC (2010) Predicting drug-target interaction networks based on functional groups and biological features. PLoS One 5(3):e9603. https://doi.org/10.1371/journal.pone.0009603
McClendon CL, Kornev AP, Gilson MK, Taylor SS (2014) Dynamic architecture of a protein kinase. Proc Natl Acad Sci U S A 111(43):E4623–E4631. https://doi.org/10.1073/pnas.1418402111
Buch I, Giorgino T, De Fabritiis G (2011) Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc Natl Acad Sci U S A 108(25):10184–10189. https://doi.org/10.1073/pnas.1103547108
Shan Y, Kim ET, Eastwood MP, Dror RO, Seeliger MA, Shaw DE (2011) How does a drug molecule find its target binding site? J Am Chem Soc 133(24):9181–9183. https://doi.org/10.1021/ja202726y
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Sohraby, F., Bagheri, M., Aryapour, H. (2019). Performing an In Silico Repurposing of Existing Drugs by Combining Virtual Screening and Molecular Dynamics Simulation. In: Vanhaelen, Q. (eds) Computational Methods for Drug Repurposing. Methods in Molecular Biology, vol 1903. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8955-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8955-3_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8954-6
Online ISBN: 978-1-4939-8955-3
eBook Packages: Springer Protocols